Topigen names new CFO
Mr Boisjoli most recently served as CFO and co-founder of Xanthus Pharmaceuticals, a Boston-based biotechnology company, where he was responsible for all financial business and operations and was
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
The Phase I clinical trial is a randomized, single-blind, placebo-controlled, single-ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of orally administered ARRY-300 in healthy volunteers. Kevin